Obinutuzumab versus Rituximab in transplant-eligible Mantle cell lymphoma patients

Obinutuzumab (O) and Rituximab (R) are two CD antibodies that have never been compared in a prospective randomised trial in mantle cell lymphoma (MCL). Herein, we report the long-term outcome of the LYMA-101 (NCT02896582) trial, in which newly diagnosed MCL patients were treated with chemotherapy pl...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2024-04
Main Authors: Sarkozy, Clémentine, Callanan, Mary Bridgid, Thieblemont, Catherine, Obéric, Lucie, Burroni, Barbara, Bouabdallah, Krimo, Damaj, Ghandi, Tessoulin, Benoit, Ribrag, Vincent, Houot, Roch, Morschhauser, Franck, Griolet, Samuel, Joubert, Clémentine, Cacheux, Victoria, Delwail, Vincent, Safar, Violaine, Gressin, Remy, Cheminant, Morgane, Delfau-Larue, Marie-Helene, Hermine, Olivier, Macintyre, Elizabeth A., Le Gouill, Steven
Format: Article
Language:fre
Subjects:
Cancer
Life Sciences
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Obinutuzumab (O) and Rituximab (R) are two CD antibodies that have never been compared in a prospective randomised trial in mantle cell lymphoma (MCL). Herein, we report the long-term outcome of the LYMA-101 (NCT02896582) trial, in which newly diagnosed MCL patients were treated with chemotherapy plus O before transplantation followed by O maintenance (O group). We then compared these patients to those treated with the same treatment design with Rituximab instead of O (R group) (NCT00921414). A propensity score matching (PSM) was used to compare the two populations (O vs R groups) in terms of MRD at the end of induction (EOI), PFS and OS. In LYMA-101, the estimated five-year PFS and OS since inclusion (n=85) were 83.4% (95%CI: 73.5-89.8%) and 86.9% (95%CI: 77.6-92.5%), respectively. At EOI, patients treated in the O group had more frequent bone marrow MRD negativity than those treated in the R group (83.1% vs 63.4% Chi2 p=0.007). The PSM resulted in 2 sets of 82 patients with comparable characteristics at inclusion. From treatment initiation, the O group had a longer estimated five-year PFS (p=0.029; 82.8% versus 66.6%, HR 1.99, IC95 1.05-3.76) and OS (p=0.039; 86.4% versus 71.4% (HR 2.08, IC95 1.01-4.16) compared to the R group. Causes of death were comparable in the 2 groups, the most common cause being lymphoma. Obinutuzumab prior to transplantation and in maintenance provides better disease control and enhances PFS and OS, as compared to Rituximab in transplant-eligible MCL patients.Clinical trial registration information: NCT00921414, NCT02896582
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.2024023944